GB0415110D0 - Substituted triazole derivatives as oxytocin antagonists - Google Patents

Substituted triazole derivatives as oxytocin antagonists

Info

Publication number
GB0415110D0
GB0415110D0 GB0415110A GB0415110A GB0415110D0 GB 0415110 D0 GB0415110 D0 GB 0415110D0 GB 0415110 A GB0415110 A GB 0415110A GB 0415110 A GB0415110 A GB 0415110A GB 0415110 D0 GB0415110 D0 GB 0415110D0
Authority
GB
United Kingdom
Prior art keywords
triazole derivatives
substituted triazole
oxytocin antagonists
oxytocin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0415110A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0415110A priority Critical patent/GB0415110D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of GB0415110D0 publication Critical patent/GB0415110D0/en
Priority to MXPA06003158A priority patent/MXPA06003158A/en
Priority to BRPI0414663-8A priority patent/BRPI0414663A/en
Priority to PCT/IB2004/002977 priority patent/WO2005028452A1/en
Priority to JP2006526721A priority patent/JP2007505888A/en
Priority to EP04769366A priority patent/EP1673355A1/en
Priority to CA2539297A priority patent/CA2539297C/en
Priority to PE2004000912A priority patent/PE20050950A1/en
Priority to UY28524A priority patent/UY28524A1/en
Priority to US10/944,959 priority patent/US7291640B2/en
Priority to ARP040103392A priority patent/AR045791A1/en
Priority to PA20048613001A priority patent/PA8613001A1/en
Priority to TW093128603A priority patent/TW200526606A/en
Priority to NL1027084A priority patent/NL1027084C2/en
Priority to US11/928,513 priority patent/US7649003B2/en
Priority to US12/621,927 priority patent/US7875615B2/en
Ceased legal-status Critical Current

Links

GB0415110A 2003-09-22 2004-07-05 Substituted triazole derivatives as oxytocin antagonists Ceased GB0415110D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists
MXPA06003158A MXPA06003158A (en) 2003-09-22 2004-09-10 Substituted triazole derivatives as oxytocin antagonists.
BRPI0414663-8A BRPI0414663A (en) 2003-09-22 2004-09-10 substituted triazole derivatives as oxytocin antagonists
PCT/IB2004/002977 WO2005028452A1 (en) 2003-09-22 2004-09-10 Substituted triazole derivatives as oxytocin antagonists
JP2006526721A JP2007505888A (en) 2003-09-22 2004-09-10 Substituted triazole derivatives as oxytocin antagonists
EP04769366A EP1673355A1 (en) 2003-09-22 2004-09-10 Substituted triazole derivatives as oxytocin antagonists
CA2539297A CA2539297C (en) 2003-09-22 2004-09-10 Substituted triazole derivatives as oxytocin antagonists
PE2004000912A PE20050950A1 (en) 2003-09-22 2004-09-20 TRIAZOLE DERIVATIVES SUBSTITUTED AS OXYTOCIN ANTAGONISTS
US10/944,959 US7291640B2 (en) 2003-09-22 2004-09-20 Substituted triazole derivatives as oxytocin antagonists
UY28524A UY28524A1 (en) 2003-09-22 2004-09-20 TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
ARP040103392A AR045791A1 (en) 2003-09-22 2004-09-21 TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
PA20048613001A PA8613001A1 (en) 2003-09-22 2004-09-21 TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
TW093128603A TW200526606A (en) 2003-09-22 2004-09-21 Substituted triazole derivatives as oxytocin antagonists
NL1027084A NL1027084C2 (en) 2003-09-22 2004-09-22 Substituted triazole derivatives as oxytocin antagonists.
US11/928,513 US7649003B2 (en) 2003-09-22 2007-10-30 Substituted triazole derivatives as oxytocin antagonists
US12/621,927 US7875615B2 (en) 2003-09-22 2009-11-19 Substituted triazole derivatives as oxytocin antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
GB0415110D0 true GB0415110D0 (en) 2004-08-11

Family

ID=32865499

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0415110A Ceased GB0415110D0 (en) 2003-09-22 2004-07-05 Substituted triazole derivatives as oxytocin antagonists

Country Status (1)

Country Link
GB (1) GB0415110D0 (en)

Similar Documents

Publication Publication Date Title
HK1113927A1 (en) Substituted triazole derivatives as oxytocin antagonists
HK1095822A1 (en) Triazole derivatives as vasopressin antagonists
EP1790650B1 (en) Novel substituted imidazole derivatives
HK1107977A1 (en) Triazole derivative
IL183538A0 (en) Substituted piperazines as cb1 antagonists
IL182828A0 (en) Constrained compounds as cgrp-receptor antagonists
IL205159A0 (en) Imidazole compounds
ZA200704809B (en) Triazole substituted aminobenzophenone compounds
IL237513A0 (en) Piperazinediones as oxytocin receptor antagonists
HK1128022A1 (en) Triazole derivatives
IL183647A (en) 3-ethylidenehydrazino substituted heterocyclic compounds
IL179888A0 (en) Compounds as ccr5 antagonists
IL179912A0 (en) Substituted diketopiperazines as oxytocin antagonists
ZA200703525B (en) Constrained compounds as CGRP-receptor antagonists
GB0415110D0 (en) Substituted triazole derivatives as oxytocin antagonists
GB0406137D0 (en) Substituted pyrazoles
GB0415888D0 (en) Triazole derivatives
GB0409502D0 (en) Triazole derivatives
GB0408789D0 (en) Triazole derivatives
GB0427944D0 (en) Pathfinder
HK1117152A1 (en) Triazole substituted aminobenzophenone compounds
SI1828148T1 (en) Triazole substituted aminobenzophenone compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)